Showing results (541-550 of 587) with videos related to

Sort By:
Pageof 59
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2017
2017 Taiwan lipid guidelines for high risk patientsYi-Heng Li, Kwo-Chang Ueng, Jiann-Shing Jeng, et al.
Journal of Medicinal Chemistry|December 22, 2005
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cellsChih Y Ho, Donald W Ludovici, Umar S M Maharoof, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Frontiers in Microbiology|July 24, 2024
The methane-oxidizing microbial communities of three maar lakes in tropical monsoon AsiaIona Eunice C Bicaldo, Karol Sophia Agape R Padilla, Tzu-Hsuan Tu, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Critical Care (London, England)|January 16, 2020
A lung rescue team improves survival in obesity with acute respiratory distress syndromeGaetano Florio, Matteo Ferrari, Edward A Bittner, et al.
Gastroenterology|July 4, 2024
Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)Virginia C Clark, Charlie Strange, Pavel Strnad, et al.
Journal of Viral Hepatitis|April 14, 2012
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment responseP J Clark, A J Thompson, M Zhu, et al.
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Pageof 59